| abstract |
The present disclosure provides engineered bacterial cells comprising a heterologous gene encoding a propionate catabolism enzyme. In another aspect, the engineered bacterial cells further comprise at least one heterologous gene encoding a transporter of propionate or a kill switch. The disclosure further provides pharmaceutical compositions comprising the engineered bacteria, and methods for treating disorders involving the catabolism of propionate, such as Propionic Acidemia and Methylmalonic Acidemia, using the pharmaceutical compositions. |